MX375061B - Modalidades mejoradas para el tratamiento de enfermedades degenerativas de la retina. - Google Patents

Modalidades mejoradas para el tratamiento de enfermedades degenerativas de la retina.

Info

Publication number
MX375061B
MX375061B MX2015009311A MX2015009311A MX375061B MX 375061 B MX375061 B MX 375061B MX 2015009311 A MX2015009311 A MX 2015009311A MX 2015009311 A MX2015009311 A MX 2015009311A MX 375061 B MX375061 B MX 375061B
Authority
MX
Mexico
Prior art keywords
retina
treatment
degenerative diseases
improved modalities
retinal
Prior art date
Application number
MX2015009311A
Other languages
English (en)
Spanish (es)
Inventor
Irina V Klimanskaya
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of MX375061B publication Critical patent/MX375061B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/062—Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
MX2015009311A 2004-01-23 2005-01-24 Modalidades mejoradas para el tratamiento de enfermedades degenerativas de la retina. MX375061B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53896404P 2004-01-23 2004-01-23
PCT/US2005/002273 WO2005070011A2 (en) 2004-01-23 2005-01-24 Improved modalities for the treatment of degenerative diseases of the retina

Publications (1)

Publication Number Publication Date
MX375061B true MX375061B (es) 2025-03-06

Family

ID=34807248

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2015009311A MX375061B (es) 2004-01-23 2005-01-24 Modalidades mejoradas para el tratamiento de enfermedades degenerativas de la retina.
MX2014001634A MX375065B (es) 2004-01-23 2005-01-24 Composiciones para usarse en el tratamiento de enfermedades degenerativas de la retina.
MX2011006096A MX343606B (es) 2004-01-23 2006-07-21 Composiciones para el tratamiento de enfermedades degenerativas de la retina.
MX2020009456A MX2020009456A (es) 2004-01-23 2006-07-21 Modalidades mejoradas para el tratamiento de enfermedades degenerativas de la retina.

Family Applications After (3)

Application Number Title Priority Date Filing Date
MX2014001634A MX375065B (es) 2004-01-23 2005-01-24 Composiciones para usarse en el tratamiento de enfermedades degenerativas de la retina.
MX2011006096A MX343606B (es) 2004-01-23 2006-07-21 Composiciones para el tratamiento de enfermedades degenerativas de la retina.
MX2020009456A MX2020009456A (es) 2004-01-23 2006-07-21 Modalidades mejoradas para el tratamiento de enfermedades degenerativas de la retina.

Country Status (15)

Country Link
US (6) US7736896B2 (enExample)
EP (8) EP4248752A3 (enExample)
JP (10) JP2007522131A (enExample)
KR (3) KR101398356B1 (enExample)
CN (3) CN1968608B (enExample)
AU (6) AU2005207042B2 (enExample)
BR (1) BRPI0507074A (enExample)
CA (2) CA2937099A1 (enExample)
ES (1) ES2721174T3 (enExample)
HK (2) HK1216068A1 (enExample)
IL (3) IL177015B (enExample)
MX (4) MX375061B (enExample)
NZ (1) NZ548929A (enExample)
SG (4) SG188122A1 (enExample)
WO (1) WO2005070011A2 (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8043614B2 (en) 2004-03-09 2011-10-25 Ahlfors Jan-Eric W Autogenic living scaffolds and living tissue matrices: methods and uses thereof
SG188122A1 (en) * 2004-01-23 2013-03-28 Advanced Cell Tech Inc Improved modalities for the treatment of degenerative diseases of the retina
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
CA3015835A1 (en) 2004-11-04 2006-05-18 Astellas Institute For Regenerative Medicine Derivation of embryonic stem cells
US7893315B2 (en) 2004-11-04 2011-02-22 Advanced Cell Technology, Inc. Derivation of embryonic stem cells and embryo-derived cells
CN1966080B (zh) * 2005-11-17 2011-06-08 李凌松 一种治疗老年痴呆症、帕金森病的神经干细胞注射液
US7541186B2 (en) * 2006-02-22 2009-06-02 University Of Washington Method of generating human retinal progenitors from embryonic stem cells
KR101602951B1 (ko) 2006-05-03 2016-03-14 오카타 세라퓨틱스, 인크. 배아 줄기 세포 및 배-유도 세포의 유도
JP5441099B2 (ja) * 2007-01-18 2014-03-12 独立行政法人理化学研究所 視細胞への分化誘導方法
EP3190178A1 (en) 2007-02-23 2017-07-12 Astellas Institute for Regenerative Medicine Highly efficient methods for reprogramming differentiated cells and for generating animals and embryonic stem cells from reprogrammed cells
ES2530370T5 (es) * 2007-04-18 2018-05-28 Hadasit Medical Research Services & Development Limited Células del epitelio pigmentario de la retina derivadas de células madre
EP2607477B1 (en) 2007-05-03 2020-09-23 The Brigham and Women's Hospital, Inc. Multipotent stem cells and uses thereof
US8574567B2 (en) 2007-05-03 2013-11-05 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
US20090028831A1 (en) * 2007-07-23 2009-01-29 University Of Kentucky Research Foundation Stem cell regulator, compositions and methods of use
ES2764473T3 (es) * 2007-10-12 2020-06-03 Astellas Inst For Regenerative Medicine Métodos mejorados para producir células RPE y composiciones de células RPE
AU2015201435B2 (en) * 2007-10-12 2017-02-02 Astellas Institute For Regenerative Medicine Improved methods of producing RPE cells and compositions of RPE cells
WO2009132156A1 (en) * 2008-04-22 2009-10-29 Regenerative Research Foundation Retinal pigment epithelial stem cells
CA3066806C (en) 2009-08-24 2023-03-07 David M. Gamm Substantially pure human retinal progenitor, forebrain progenitor, and retinal pigment epithelium cell cultures and methods of making the same
WO2011063005A2 (en) 2009-11-17 2011-05-26 Advanced Cell Technology, Inc. Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
EP4245370A3 (en) 2010-07-12 2023-11-29 University of Southern California Biocompatible substrate for facilitating interconnections between stem cells and target tissues and methods for implanting same
ES2874953T3 (es) 2010-07-23 2021-11-05 Astellas Inst For Regenerative Medicine Métodos para la detección de subpoblaciones raras de células y composiciones muy purificadas de células
JP2012231786A (ja) * 2011-04-18 2012-11-29 Kyushu Univ 標的遺伝子の発現変化による食品機能成分及び医薬品感受性評価方法
US10478206B2 (en) 2011-04-29 2019-11-19 University Of Southern California Instruments and methods for the implantation of cell-seeded substrates
US8877489B2 (en) 2011-12-05 2014-11-04 California Institute Of Technology Ultrathin parylene-C semipermeable membranes for biomedical applications
JP6189829B2 (ja) 2011-05-13 2017-08-30 ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンティド・バイ・ザ・セクレタリー・フォー・ザ・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシズ Ｚｓｃａｎ４とｚｓｃａｎ４依存性遺伝子を利用した体細胞の直接的な再プログラム化
JP6223963B2 (ja) * 2011-05-18 2017-11-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 網膜疾患を処置するための組成物および方法
WO2013015835A1 (en) 2011-07-22 2013-01-31 Seven Networks, Inc. Mobile application traffic optimization
CN103007355B (zh) * 2011-09-20 2014-08-13 同济大学 一种水凝胶-纳米纤维膜及其制备方法和用途
CA2855941A1 (en) * 2011-11-14 2013-05-23 Advanced Cell Technology, Inc. Pharmaceutical preparations of human rpe cells and uses thereof
KR102108245B1 (ko) 2011-11-30 2020-05-08 아스텔라스 인스티튜트 포 리제너러티브 메디슨 중간엽 간질 세포 및 이에 관련된 용도
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
US9248013B2 (en) 2011-12-05 2016-02-02 California Institute Of Technology 3-Dimensional parylene scaffold cage
EP3492586B1 (en) * 2012-02-17 2024-04-17 Schepens Eye Research Institute Phenotype profile of human retinal progenitor cells
US10519422B2 (en) 2012-02-29 2019-12-31 Riken Method of producing human retinal pigment epithelial cells
CN104471059B (zh) 2012-07-12 2018-04-17 珠海横琴爱姆斯坦生物科技有限公司 人胚胎干细胞衍生的间充质样干细胞、方法及其应用
US11033586B2 (en) * 2012-08-24 2021-06-15 Riken Method for producing retinal pigment epithelial cell sheet
AU2014233403B2 (en) * 2013-03-15 2019-08-01 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US11241460B2 (en) 2013-03-15 2022-02-08 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
WO2014157257A1 (ja) * 2013-03-25 2014-10-02 公益財団法人先端医療振興財団 細胞の選別方法
EP2796545A1 (en) * 2013-04-26 2014-10-29 Université Pierre et Marie Curie (Paris 6) Methods for obtaining retinal progenitors, retinal pigmented epithelial cells and neural retinal cells
RU2704984C1 (ru) 2013-11-27 2019-11-01 Киото Прифекчурал Паблик Юниверсити Корпорэйшн Применение ламинина в культуре клеток эндотелия роговицы
EP3080248A1 (en) 2013-12-11 2016-10-19 Pfizer Limited Method for producing retinal pigment epithelial cells
WO2016067629A1 (ja) * 2014-10-31 2016-05-06 京都府公立大学法人 ラミニンによる網膜および神経の新規治療
CN113559246A (zh) 2014-10-31 2021-10-29 京都府公立大学法人 使用层粘连蛋白的新的角膜的治疗
EP4343331A3 (en) 2015-03-23 2024-06-19 Astellas Institute for Regenerative Medicine Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors
AU2016308818B2 (en) 2015-08-18 2022-04-21 Astellas Institute For Regenerative Medicine Clinical formulations
ES2970537T3 (es) 2015-09-08 2024-05-29 Us Health Método para la diferenciación reproducible de células epiteliales del pigmento retiniano de calidad clínica
ES2922475T3 (es) 2015-09-08 2022-09-15 Sumitomo Pharma Co Ltd Método para producir células epiteliales pigmentarias de la retina
AU2016318774B2 (en) 2015-09-08 2022-08-18 FUJIFILM Cellular Dynamics, Inc. MACS-based purification of stem cell-derived retinal pigment epithelium
US10865381B2 (en) 2015-10-20 2020-12-15 FUJIFILM Cellular Dynamics, Inc. Multi-lineage hematopoietic precursor cell production by genetic programming
CN106609256B (zh) * 2015-10-22 2020-04-07 同济大学 体外诱导人胚胎干细胞分化为视网膜色素上皮细胞的方法
CN106609255B (zh) * 2015-10-22 2019-11-05 同济大学 含pj34和视网膜色素上皮细胞的细胞悬液及其应用
CN106609257B (zh) * 2015-10-22 2020-04-10 同济大学 高效分离体外诱导的rpe细胞和rpc的方法
CN106609263B (zh) * 2015-10-22 2020-04-07 同济大学 高效诱导多能干细胞向视网膜色素上皮细胞分化的方法
CN106282096A (zh) * 2016-10-19 2017-01-04 江苏艾尔康生物医药科技有限公司 一种人类视网膜色素上皮细胞层的分离培养方法
CA3055706A1 (en) 2017-03-08 2018-09-13 Sumitomo Dainippon Pharma Co., Ltd. Method for producing retinal pigment epithelial cells
CN110913874A (zh) * 2017-03-16 2020-03-24 谱系细胞疗法公司 用于测量视网膜疾病疗法的疗效的方法
MX2019011897A (es) 2017-04-18 2019-11-28 Fujifilm Cellular Dynamics Inc Celulas efectoras inmunitarias especificas de antigenos.
US20200277571A1 (en) * 2017-09-14 2020-09-03 Riken Method for amplifying cone photoreceptors or rod photoreceptors using dorsalization signal transmitter or ventralization signal transmitter
CR20200210A (es) 2017-11-15 2020-09-23 Friedrich Miescher Institute For Biomedical Res Promotor especìfico de las cèlulas del epitelio pigmentario retinal en primates
CN108029638B (zh) * 2017-12-04 2020-04-21 四川省人民医院 一种视网膜色素变性疾病动物模型的构建方法及应用
US11946069B2 (en) 2018-03-12 2024-04-02 RxCell, Inc. Method for generating multiple cellular products from single pluripotent cell source
TWI820330B (zh) * 2019-04-26 2023-11-01 國立研究開發法人理化學研究所 包含神經視網膜與視網膜色素上皮細胞與水凝膠之複合體及其製造方法
MX2022005134A (es) 2019-10-30 2022-05-30 Astellas Inst For Regenerative Medicine Metodos para producir celulas del epitelio pigmentario retiniano.
RU2730937C1 (ru) * 2019-11-01 2020-08-26 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ГБ им. Гельмгольца" Миндрава России) Способ трансплантации клеток ретинального пигментного эпителия (РПЭ), дифференцированных из индуцированных плюрипотентных стволовых клеток человека, при атрофии ретинального пигментного эпителия
EP4306634A4 (en) 2021-03-09 2025-03-26 Riken METHOD FOR PRODUCING HYPOIMMUNOGENIC RETINAL PIGMENT EPITHELIAL CELLS
US20250019652A1 (en) 2021-11-19 2025-01-16 Riken Production method for sheet-like retinal tissue
US20250188412A1 (en) 2022-03-16 2025-06-12 Sumitomo Pharma Co., Ltd. Transplantation medium
WO2023201361A1 (en) 2022-04-15 2023-10-19 Aspen Neuroscience, Inc. Methods of classifying the differentiation state of cells and related compositions of differentiated cells
WO2024172043A1 (ja) 2023-02-14 2024-08-22 住友ファーマ株式会社 網膜色素上皮裂孔の治療薬

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69329556D1 (de) 1993-04-30 2000-11-16 Photogenesis Inc Transplantation des retinalen pigmentepithels
US6878544B2 (en) 1996-04-19 2005-04-12 Neurotech Sa Retinal cell lines with extended life-span and their applications
US20040086494A1 (en) * 1996-10-07 2004-05-06 John Constance Mary Immune privileged cells for delivery of proteins and peptides
EP0986635A4 (en) 1997-01-10 2001-11-07 Life Technologies Inc SERUM SUBSTITUTE FOR EMBRYONIC STEM CELLS
US6331406B1 (en) * 1997-03-31 2001-12-18 The John Hopkins University School Of Medicine Human enbryonic germ cell and methods of use
WO1999034834A1 (en) 1998-01-02 1999-07-15 Titan Pharmaceuticals, Inc. Use of pigmented retinal epithelial cells for creation of an immune privilege site
CA2321203A1 (en) 1998-03-02 1999-09-10 Compucyte Corp. Selective cell analysis
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
JP2003514516A (ja) 1999-10-28 2003-04-22 ユニバーシティ オブ マサチューセッツ 多能性細胞と細胞株の雌性発生的または雄性発生的産生および分化した細胞と組織を産生するためのその使用
JP3454206B2 (ja) * 1999-11-10 2003-10-06 三菱電機株式会社 雑音抑圧装置及び雑音抑圧方法
WO2001050848A2 (en) * 2000-01-07 2001-07-19 Oregon Health And Science University Clonal propagation of primate offspring by embryo splitting
US6602711B1 (en) * 2000-02-21 2003-08-05 Wisconsin Alumni Research Foundation Method of making embryoid bodies from primate embryonic stem cells
US20030084471A1 (en) * 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
US6458589B1 (en) 2000-04-27 2002-10-01 Geron Corporation Hepatocyte lineage cells derived from pluripotent stem cells
US20040053869A1 (en) 2000-08-19 2004-03-18 Peter Andrews Stem cell differentiation
US6576464B2 (en) 2000-11-27 2003-06-10 Geron Corporation Methods for providing differentiated stem cells
US6699493B2 (en) 2000-11-29 2004-03-02 Oculex Pharmaceuticals, Inc. Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
DE10108412B4 (de) * 2001-02-21 2006-03-09 Cevec Pharmaceuticals Gmbh Pigmentepithelzelle des Auges, ihre Herstellung und Verwendung in der Therapie einer Augen- oder Nervenerkrankung
EP1393066A4 (en) 2001-05-15 2006-01-25 Rappaport Family Inst For Res INSULIN-PRODUCING CELLS DERIVED FROM HUMAN EMBRYONIC STEM CELLS
IL159580A0 (en) 2001-07-12 2004-06-01 Geron Corp Cells of the cardiomyocyte lineage produced from human pluripotent stem cells
WO2003046141A2 (en) * 2001-11-26 2003-06-05 Advanced Cell Technology, Inc. Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
AU2002366641A1 (en) 2001-12-11 2003-06-23 Fibrogen, Inc. Methods for inhibiting ocular processes
CA2482904A1 (en) 2002-04-18 2003-10-23 Lynkeus Biotech Gmbh Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification
US7422736B2 (en) 2002-07-26 2008-09-09 Food Industry Research And Development Institute Somatic pluripotent cells
US7824671B2 (en) * 2002-10-04 2010-11-02 Tissuetech, Inc. Retinal pigment epithelial cell cultures on amniotic membrane and transplantation
JP4348706B2 (ja) * 2002-10-08 2009-10-21 日本電気株式会社 アレイ装置および携帯端末
AU2003302020B2 (en) * 2002-11-14 2008-01-31 Ethicon Endo-Surgery, Inc. Methods and devices for detecting tissue cells
EP1599730A2 (en) * 2003-03-03 2005-11-30 Kouyama, Yoshihisa Methods and apparatus for use in detection and quantitation of various cell types and use of optical bio-disc for performing same
US7794704B2 (en) * 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
SG188122A1 (en) 2004-01-23 2013-03-28 Advanced Cell Tech Inc Improved modalities for the treatment of degenerative diseases of the retina
CA3015835A1 (en) 2004-11-04 2006-05-18 Astellas Institute For Regenerative Medicine Derivation of embryonic stem cells
CN102220280A (zh) 2005-02-11 2011-10-19 新加坡科技研究局 增殖干细胞的方法
KR100832592B1 (ko) 2006-08-17 2008-05-27 박현숙 폴리머 막을 이용한 줄기세포와 피더세포의 공배양방법
ES2530370T5 (es) * 2007-04-18 2018-05-28 Hadasit Medical Research Services & Development Limited Células del epitelio pigmentario de la retina derivadas de células madre
JP2008307007A (ja) * 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
ES2764473T3 (es) 2007-10-12 2020-06-03 Astellas Inst For Regenerative Medicine Métodos mejorados para producir células RPE y composiciones de células RPE
HU0700675D0 (en) 2007-10-15 2007-12-28 Mta Tamogatott Kutatohelyek Ir Method for monitoring stem cell differentiation
US20090233324A1 (en) * 2008-03-11 2009-09-17 Kopf-Sill Anne R Methods for Diagnosing Cancer Using Samples Collected From A Central Vein Location or an Arterial Location
US8652123B2 (en) * 2008-09-02 2014-02-18 Geoffrey C. GURTNER Methods and devices for improving the appearance of tissue
WO2011063005A2 (en) * 2009-11-17 2011-05-26 Advanced Cell Technology, Inc. Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
ES2874953T3 (es) 2010-07-23 2021-11-05 Astellas Inst For Regenerative Medicine Métodos para la detección de subpoblaciones raras de células y composiciones muy purificadas de células
EP2702135B1 (en) 2011-04-29 2019-04-17 University of Southern California Method of cryopreservation of stem cell-derived retinal pigment epithelial cells on polymeric substrate
CA2855941A1 (en) * 2011-11-14 2013-05-23 Advanced Cell Technology, Inc. Pharmaceutical preparations of human rpe cells and uses thereof
US9850463B2 (en) 2012-02-01 2017-12-26 The Regents Of The University Of California Methods of culturing retinal pigmented epithelium cells, including xeno-free production, RPE enrichment, and cryopreservation
ES2688019T3 (es) 2012-06-05 2018-10-30 The Regents Of The University Of California Métodos y composiciones para la producción acelerada de células epiteliales pigmentadas retinianas a partir de células pluripotentes

Also Published As

Publication number Publication date
EP2438816B1 (en) 2019-03-27
HK1216068A1 (en) 2016-10-14
KR101258292B1 (ko) 2013-04-25
IL177015A0 (en) 2006-12-10
HK1162931A1 (en) 2012-09-07
US9040770B2 (en) 2015-05-26
CN102204930B (zh) 2014-12-03
JP2016195862A (ja) 2016-11-24
JP2015096556A (ja) 2015-05-21
EP4248752A3 (en) 2024-01-03
CA2555370C (en) 2024-02-06
WO2005070011A3 (en) 2005-10-13
ES2721174T3 (es) 2019-07-29
CN1968608A (zh) 2007-05-23
AU2005207042B2 (en) 2010-09-09
CA2555370A1 (en) 2005-08-04
KR20120051754A (ko) 2012-05-22
SG155236A1 (en) 2009-09-30
US9649340B2 (en) 2017-05-16
CA2937099A1 (en) 2005-08-04
US20150328261A1 (en) 2015-11-19
MX375065B (es) 2025-03-06
US9730962B2 (en) 2017-08-15
MX343606B (es) 2016-11-11
AU2021200601A1 (en) 2021-03-04
EP1708575A2 (en) 2006-10-11
EP2438815A2 (en) 2012-04-11
EP4248751A3 (en) 2023-11-01
US20180064761A1 (en) 2018-03-08
EP4248752A2 (en) 2023-09-27
JP2018086274A (ja) 2018-06-07
KR101398356B1 (ko) 2014-05-23
JP2012148085A (ja) 2012-08-09
JP2022153630A (ja) 2022-10-12
EP2438815A3 (en) 2012-10-03
EP1708575A4 (en) 2009-07-01
SG10201606441SA (en) 2016-09-29
HK1207821A1 (en) 2016-02-12
BRPI0507074A (pt) 2007-06-19
IL291162A (en) 2022-05-01
EP2438814A2 (en) 2012-04-11
AU2019200513A1 (en) 2019-02-14
MX2020009456A (es) 2020-10-12
EP2438814A3 (en) 2012-10-03
JP2024038460A (ja) 2024-03-19
US20110117062A1 (en) 2011-05-19
EP4269561A2 (en) 2023-11-01
AU2016259323A1 (en) 2016-12-01
AU2005207042A1 (en) 2005-08-04
CN104434979A (zh) 2015-03-25
SG10201912182UA (en) 2020-02-27
EP2438816A2 (en) 2012-04-11
JP2007522131A (ja) 2007-08-09
AU2010249263A1 (en) 2011-01-06
AU2013201791A1 (en) 2013-04-11
WO2005070011A2 (en) 2005-08-04
US20100299765A1 (en) 2010-11-25
JP2019217356A (ja) 2019-12-26
JP2014079650A (ja) 2014-05-08
AU2016259323B2 (en) 2019-01-31
AU2010249263B2 (en) 2013-04-18
EP4269561A3 (en) 2024-01-03
IL177015B (en) 2019-06-30
JP2020146575A (ja) 2020-09-17
US7736896B2 (en) 2010-06-15
SG188122A1 (en) 2013-03-28
US20060018886A1 (en) 2006-01-26
NZ548929A (en) 2010-10-29
IL267126A (en) 2019-08-29
US7795025B2 (en) 2010-09-14
US20070031386A1 (en) 2007-02-08
KR20070069087A (ko) 2007-07-02
CN102204930A (zh) 2011-10-05
CN1968608B (zh) 2011-06-29
EP2438816A3 (en) 2012-10-03
KR20130025953A (ko) 2013-03-12
AU2013201791B2 (en) 2016-08-18
EP4248751A2 (en) 2023-09-27
IL267126B (en) 2022-04-01
EP2929782A1 (en) 2015-10-14

Similar Documents

Publication Publication Date Title
MX375061B (es) Modalidades mejoradas para el tratamiento de enfermedades degenerativas de la retina.
WO2006080952A3 (en) Improved modalities for the treatment of degenerative diseases of the retina
Wiley et al. Patient-specific induced pluripotent stem cells (iPSCs) for the study and treatment of retinal degenerative diseases
WO2008157791A3 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
EP2279247A4 (en) STEM CELLS OF THE RETINAL PIGMENTARY EPITHELIUM
TW200732347A (en) VEGF analogs and methods of use
WO2009089635A9 (en) Treating neurodegenerative diseases with progranulin (pgrn)
WO2011063005A3 (en) Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
ECSP11011067A (es) Compuestos para el tratamiento de enfermedades y desórdenes oftalmológicos
MY194587A (en) Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
CR11561A (es) Proteinas de union a antigenos
AU2007257423A8 (en) Purine analogs
WO2020093018A8 (en) A codon optimized otoferlin aav dual vector gene therapy
BR112017014332A2 (pt) métodos de tratamento de doenças retinianas
MX2009012645A (es) Formulaciones y metodos para tratar el ojo seco.
EA200901067A1 (ru) Использование семафорина 6а в качестве промотора миелинизации и дифференцировки олигодендроцитов
WO2008060362A3 (en) Methods and compositions for the treatment of skin diseases and disorders
CL2018002430A1 (es) Proteínas de fusión de enzimas lisosomales terapéuticas dirigidas, formulaciones asociadas y usos de las mismas
CA3043675C (en) Joint implant for new tissue formation at the joint
WO2016100820A3 (en) Fgf2 truncations and mutants and uses thereof
NZ602479A (en) Pharmaceutical composition for the treatment of dry eye and/or corneal and conjunctival lesion
DE502005008759D1 (de) In vitro aus knochenmarkstammzellen differenzierteerwendung
WO2013067076A3 (en) Methods and compositions for neuroprotection
WO2007035722A8 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
WO2007088051A3 (en) Modulation of mdl-1 activity for treatment of inflammatory disease